RAPT Therapeutics Q2 EPS $(0.71) Beats $(0.72) Estimate
Portfolio Pulse from Benzinga Newsdesk
RAPT Therapeutics (NASDAQ:RAPT) reported a Q2 EPS of $(0.71), beating the analyst consensus estimate of $(0.72) by 1.39%. This represents a 7.58% increase in losses compared to the same period last year.
August 08, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RAPT Therapeutics reported a Q2 EPS of $(0.71), beating the analyst consensus estimate of $(0.72) by 1.39%. However, this is a 7.58% increase in losses compared to the same period last year.
The slight beat on EPS estimates is a positive signal for investors, indicating that the company is performing slightly better than expected. However, the increase in losses compared to the same period last year may temper enthusiasm.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100